Morphosys Licenses Antibodies to Proteomika for Use in Companion Dxs

Proteomika plans to launch kits in the second quarter of this year containing the HuCAL antibodies that can help monitor certain biopharmaceutical therapies.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.